https://www.nature.com/articles/d41586-023-03968-6 Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Advertisement Nature * View all journals * Search * Log in * Explore content * About the journal * Publish with us * Subscribe * Sign up for alerts * RSS feed 1. nature 2. news 3. article * NEWS * 12 December 2023 'It's all gone': CAR-T therapy forces autoimmune diseases into remission Engineered immune cells, most commonly used to treat cancers, show their power against lupus and other immune disorders. By * Heidi Ledford 1. Heidi Ledford View author publications You can also search for this author in PubMed Google Scholar * Twitter * Facebook * Email Composite coloured scanning electron micrograph (SEM) of T-cells (small round) and a cervical cancer cell (Hela) T cells (smaller cells) can be engineered to recognize cancer cells -- and also other immune cells.Credit: Steve Gschmeissner/Science Photo Library Engineered immune cells have given 15 people with once-debilitating autoimmune disorders a new lease on life, free from fresh symptoms or treatments. The results raise hopes that the approach -- called CAR-T-cell therapy -- might one day be extended to a variety of other conditions fuelled by rogue immune cells that produce antibodies against the body's own tissues. All 15 participants, who each had one of three autoimmune conditions, have remained disease-free or nearly so since their treatment, according to data presented on 9 December at the American Society of Hematology meeting in San Diego, California. The first participants were treated more than two years ago. These successes, although preliminary, have been electric, says Marco Ruella, an oncologist at the University of Pennsylvania in Philadelphia. "We're all excited," he says. "There's a lot of potential." Bespoke immune cells CAR-T therapies harness the immune players called T cells. T cells are removed from the person being treated, genetically engineered to produce proteins called chimeric antigen receptors (CARs) and then reintroduced to the person's body. In many therapies, the T cells are tailored to recognize a protein made by immune cells called B cells. When reintroduced, the CAR T cells will target the B cells for destruction -- a useful feature for treating cancers caused by abnormal B cells. [d41586-023] The race to supercharge cancer-fighting T cells B cells also drive some autoimmune disorders by making antibodies that attack healthy tissue. In 2019, researchers showed that CAR T cells that recognize B cells reduced symptoms in mice with a disease similar to lupus, an autoimmune disorder that affects a variety of organs^1. Around the same time, researchers at University Hospital Erlangen in Germany were setting up their own CAR-T centre to provide cancer treatment. During a meeting at the centre, a rheumatologist asked the cancer specialists for advice about a young woman with a form of lupus called systemic lupus erythematosus. Several of her organs were failing; her doctors estimated that she did not have long to live. The young woman insisted that they try something new. High-risk approach The team thought of the mouse study but baulked at trying it in people. CAR-T therapy can have severe side effects, and recipients must first undergo intensive chemotherapy that kills off many of their existing immune cells. "At the beginning we were quite scared," said team member Fabian Muller, an oncologist at the Friedrich-Alexander University of Erlangen-Nuremberg, at a press conference before he presented the work at the San Diego meeting. The woman was adamant that they try. That first participant -- and the others who followed -- experienced relatively minor adverse effects, Muller reported at the conference. The Erlangen team eventually used the method to treat two other autoimmune disorders: systemic sclerosis and idiopathic inflammatory myositis. The successes continued. [d41586-023] Cancer treatments boosted by immune-cell hacking Other groups have since taken up the approach and reported similar results. Earlier this month, another team added a fourth autoimmune disorder called myasthenia gravis to the list of successes^2. Researchers are beginning to wonder how long the final list will be. "We're just at the beginning," says Marcela Maus, who designs CAR-T therapies against cancer at Massachusetts General Hospital in Boston. "There is so much that can be done that was unthinkable just a decade ago." At this stage, however, it's unclear how much of this success is due to the CAR-T therapy as opposed to the chemotherapy that killed many of the participants' pre-existing immune cells, cautions Ruella. That might have helped to wipe out the errant B cells. For now, Muller lapses into a dreamy smile as he marvels over the remarkable recoveries he has seen: the man who struggled to walk 10 metres before his treatment and now routinely walks 10 kilometres around town, for example. "These are young people that have been spending more time with their doctors than with their friends," he says. "They would describe their breakfast as a handful of pills that they are just shoving in." "And it's all gone," he says. "From the physician perspective, it's pretty much the most pleasing thing." doi: https://doi.org/10.1038/d41586-023-03968-6 References 1. Kansal, R. et al. Sci. Transl. Med. 11, eaav1648 (2019). Article PubMed Google Scholar 2. Haghikia, A. et al. Lancet Neurol. 22, 1104-1105 (2023). Article PubMed Google Scholar Download references Reprints and Permissions Related Articles * [d41586-023] Last-resort cancer therapy holds back disease for more than a decade * [d41586-023] Regulatory T cells subdue an autoimmune disease * [d41586-023] Could CAR-T-cell therapy offer hope to children with cancer? * [d41586-023] CRISPR cancer trial success paves the way for personalized treatments * [d41586-023] Research round-up: autoimmune disease Subjects * Immunology * Medical research * Biotechnology Latest on: Immunology Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques Article 14 DEC 23 Nature's 10: ten people (and one non-human) who helped shape science in 2023 Nature's 10: ten people (and one non-human) who helped shape science in 2023 News Feature 13 DEC 23 Malaria fighter: this researcher paved the way for a game-changing vaccine Malaria fighter: this researcher paved the way for a game-changing vaccine News Feature 13 DEC 23 Medical research The cancer physician who helped to deliver a life-extending treatment The cancer physician who helped to deliver a life-extending treatment News Feature 13 DEC 23 Weight-loss-drug pioneer: this biochemist finally gained recognition for her work Weight-loss-drug pioneer: this biochemist finally gained recognition for her work News Feature 13 DEC 23 GDF15 linked to maternal risk of nausea and vomiting during pregnancy Article 13 DEC 23 Biotechnology Modeling post-implantation human development to yolk sac blood emergence Article 13 DEC 23 Australian Indigenous genomes are highly diverse and unlike those anywhere else Australian Indigenous genomes are highly diverse and unlike those anywhere else News 13 DEC 23 The landscape of genomic structural variation in Indigenous Australians The landscape of genomic structural variation in Indigenous Australians Article 13 DEC 23 Nature Careers Jobs * Postdoctoral / Research Scientist positions in Molecular Immunology / Cancer Immunology Dallas, Texas (US) The University of Texas Southwestern Medical Center (UT Southwestern Medical Center) [] * Eight Professorship Calls - Geoscience, Green Transition and Climate Research The Geological Survey of Denmark and Greenland (GEUS) is an independent research institution under the Danish Ministry of Climate, Energy and Utili... Copenhagen, Hovedstaden (DK) GEUS [] * W3 Research Professor for Media-Supported Learning in Informal and Extracurricular Learning Venues The Psychology Department of the Faculty of Science at University of Tubingen and the independent Leibniz-Institut fur Wissensmedien (IWM) are seek... Tubingen, Baden-Wurttemberg (DE) Leibniz-Institut fur Wissensmedien (IWM) [] * Assistant Professor (Research) The Department of Surgery, Division of Urology of McGill University is inviting applicants for a position at the rank of Assistant Professor. Montreal, Quebec (CA) McGill University - Faculty of Medicine and Health Sciences - Department of Surgery [] * Diabetes Faculty The College of Health Sciences invites applications for faculty positions in the Diabetes Program. Qatar (QA) University of Doha for Science and Technology [] You have full access to this article via your institution. Download PDF Related Articles * [d41586-023] Last-resort cancer therapy holds back disease for more than a decade * [d41586-023] Regulatory T cells subdue an autoimmune disease * [d41586-023] Could CAR-T-cell therapy offer hope to children with cancer? * [d41586-023] CRISPR cancer trial success paves the way for personalized treatments * [d41586-023] Research round-up: autoimmune disease Subjects * Immunology * Medical research * Biotechnology Advertisement Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up * Close Nature Briefing Sign up for the Nature Briefing newsletter -- what matters in science, free to your inbox daily. Email address [ ] Sign up [ ] I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content * Research articles * News * Opinion * Research Analysis * Careers * Books & Culture * Podcasts * Videos * Current issue * Browse issues * Collections * Subjects * Follow us on Facebook * Follow us on Twitter * Subscribe * Sign up for alerts * RSS feed About the journal * Journal Staff * About the Editors * Journal Information * Our publishing models * Editorial Values Statement * Journal Metrics * Awards * Contact * Editorial policies * History of Nature * Send a news tip Publish with us * For Authors * For Referees * Language editing services * Submit manuscript Search Search articles by subject, keyword or author [ ] Show results from [All journals] Search Advanced search Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap About Nature Portfolio * About us * Press releases * Press office * Contact us Discover content * Journals A-Z * Articles by subject * Protocol Exchange * Nature Index Publishing policies * Nature portfolio policies * Open access Author & Researcher services * Reprints & permissions * Research data * Language editing * Scientific editing * Nature Masterclasses * Live Expert Trainer-led workshops * Research Solutions Libraries & institutions * Librarian service & tools * Librarian portal * Open research * Recommend to library Advertising & partnerships * Advertising * Partnerships & Services * Media kits * Branded content Professional development * Nature Careers * Nature Conferences Regional websites * Nature Africa * Nature China * Nature India * Nature Italy * Nature Japan * Nature Korea * Nature Middle East * Privacy Policy * Use of cookies * Your privacy choices/Manage cookies * Legal notice * Accessibility statement * Terms & Conditions * Your US state privacy rights Springer Nature (c) 2023 Springer Nature Limited